Sagimet Biosciences Inc.

NASDAQ: SGMT · Real-Time Price · USD
7.68
-0.99 (-11.42%)
At close: Aug 15, 2025, 3:59 PM
7.83
1.95%
After-hours: Aug 15, 2025, 07:47 PM EDT

Sagimet Biosciences Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
75.84M 75.14M 158K 56.73M
Short-Term Investments
75.41M 19.76M 32.19M n/a
Long-Term Investments
7.41M n/a n/a n/a
Other Long-Term Assets
n/a n/a 27K 27K
Receivables
n/a n/a n/a n/a
Inventory
n/a n/a n/a n/a
Other Current Assets
463K 397K 95K 1.51M
Total Current Assets
152.77M 96.65M 32.79M 58.66M
Property-Plant & Equipment
77K 73K 212K 342K
Goodwill & Intangibles
n/a n/a n/a n/a
Total Long-Term Assets
7.49M 73K 239K 369K
Total Assets
160.26M 96.72M 33.03M 59.03M
Account Payables
1.43M 186K 1.13M 761K
Deferred Revenue
n/a n/a 3.96M n/a
Short-Term Debt
78K 65K 133K 124K
Other Current Liabilities
-73K 491K -4.04M 61K
Total Current Liabilities
4.45M 5.65M 5.28M 2.44M
Long-Term Debt
n/a n/a n/a n/a
Other Long-Term Liabilities
n/a n/a 4K 214.63M
Total Long-Term Liabilities
n/a n/a 214.7M 214.85M
Total Liabilities
4.45M 5.65M 219.98M 217.29M
Total Debt
78K 65K 211K 348K
Common Stock
3K 2K 1K 1K
Retained Earnings
-295.31M -249.74M -221.87M -191.37M
Comprehensive Income
230K 30K -84K -214.63M
Shareholders Equity
155.81M 91.06M 27.67M 56.37M
Total Investments
82.82M 19.76M 32.19M n/a